| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 18 -> 27 locations |
| 2026-06-03 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 12 -> 18 locations |
| 2026-05-23 | NCT05714839 A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of… |
Trial sites expanded: 27 -> 30 locations |
| 2026-05-16 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 6 -> 10 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-09 | NCT07637526 Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed… | Not Yet Recruiting | |
| 2026-05-29 | NCT07614360 Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib… | Phase 2 | Not Yet Recruiting |
| 2026-05-27 | NCT07609706 A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd)… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06679101 | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and… | Multiple Myeloma | Recruiting |
| NCT04162210 | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose… | Multiple Myeloma | Active, Not Recruiting |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone… | Multiple Myeloma | Active, Not Recruiting |
| NCT06868654 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin… | Multiple Myeloma | Active, Not Recruiting |
| NCT06868667 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin… | Multiple Myeloma | Active, Not Recruiting |
| Phase 2 | |||
| NCT05922501 | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | Relapsed Cancer | Recruiting |
| NCT05847569 | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of… | Recurrent Multiple Myeloma | Recruiting |
| NCT05091372 | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and… | Myeloma Multiple | Recruiting |
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… | Multiple Myeloma | Recruiting |
| NCT05874193 | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma | Relapsed/Refractory Multiple Myeloma | Not Yet Recruiting |
| NCT04802356 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | Multiple Myeloma | Active, Not Recruiting |
| NCT07224672 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… | Amyloidosis | Not Yet Recruiting |
| NCT04680468 | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and… | Myeloma | Active, Not Recruiting |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients… | Plasma Cell Myeloma | Active, Not Recruiting |
| NCT07614360 | Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib… | Multiple Myeloma | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06232044 | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With… | Recurrent Multiple Myeloma | Recruiting |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | Plasma Cell Myeloma Refractory | Recruiting |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | AL Amyloidosis | Recruiting |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of… | Multiple Myeloma | Recruiting |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Multiple Myeloma | Active, Not Recruiting |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer… | Multiple Myeloma | Active, Not Recruiting |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in… | Multiple Myeloma | Active, Not Recruiting |
| NCT05060627 | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed… | Relapsed Multiple Myeloma | Active, Not Recruiting |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy… | Multiple Myeloma | Active, Not Recruiting |
| Phase 1 | |||
| NCT05055063 | A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of… | Myeloma | Recruiting |